Accordingly, ADENO showed no LAG-3 expression and therefore might not be a good candidate for extended immunotherapy targeting LAG-3, in contrast to SCC, whereas TIGIT showed similar expression in both tumor entities. The gene discussed is LAG3; the disease is neoplasm.